Five Star Equities Issues New Research Reports on ARQL, CYTK, HALO and PRAN


Follow this company

Companies Mentioned

NASDAQ:ARQL / NASDAQ:CYTK / NASDAQ:HALO / NASDAQ:PRAN
09/04/2013 [ACCESSWIRE]

Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com/ and get exclusive access to our numerous stock reports.

ArQule, Inc. (NASDAQ: ARQL) shares dropped 10.75 percent to close at $2.49 a share Tuesday. The stock traded between $2.24 and $2.62 on volume of 736,188 shares traded. The company announced that it will lower the dose of tivantinib, its experimental liver cancer treatment, for the second time. Shares of ArQule have fallen approximately 10.0 percent year-to-date.

Get more information on ArQule and free access to the in-depth equity report at:  
www.FiveStarEquities.com/ARQL

Cytokinetics, Inc. (NASDAQ: CYTK) shares dropped 26.93percent to close at $7.65 a share Tuesday. The stock traded between $7.62 and $8.74 on volume of 6.94 million shares traded. The company announced that its heart failure drug failed to meet its primary endpoint in a recent study. Shares of Cytokinetics have gained approximately 93.0 percent year-to-date.

Get more information on Cytokinetics and free access to the in-depth equity report at:  
www.FiveStarEquities.com/CYTK

Halozyme Therapeutics, Inc. (NASDAQ: HALO) shares increased 2.89 percent to close at $8.55 share Tuesday. The stock traded between $8.34 and $8.94 on volume of 3.44 million shares traded. The company announced "that the European Commission has granted Roche European Union (EU) marketing authorization for the use of a time-saving subcutaneous formulation of Herceptin (trastuzumab) for the treatment of HER2-positive breast cancer." Shares of Halozyme Therapeutics have gained approximately 27.0 percent year-to-date.

Get more information on Halozyme Therapeutics and free access to the in-depth equity report at:  
www.FiveStarEquities.com/HALO

Prana Biotechnology Limited (NASDAQ: PRAN) shares gained 8.23 percent to close at $5.39 a share Tuesday. The stock traded between $5.20 and $5.57 on volume of 950,918 shares traded. The company recently announced that Elsevier Business Intelligence has named PBT2 as one of the Top 10 Neuroscience Projects to Watch. Shares of Prana Biotechnology have gained approximately 145.0 percent year-to-date.

Get more information on Prana Biotechnology and free access to the in-depth equity report at:  
www.FiveStarEquities.com/PRAN

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.

Contact:   
Five Star Equities
info@fivestarequities.com

COMMENTS

Leave a comment...
 * 

Your Name
 *